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Abstract
Introduction: Autoimmune hemolytic anemia in children younger than 2 years of age is usually
characterized by a severe course, with a mortality rate of approximately 10%. The prolonged
immunosuppression following specific treatment may be associated with a high risk of developing severe
infections. Recently, theuseofmonoclonalantibodies(rituximab)has allowedsustainedremissions to be
obtained in the majority of pediatric patients with refractory autoimmune hemolytic anemia.
Case presentation: We describe the case of an 8-month-old Caucasian girl affected by a severe
form of autoimmune hemolytic anemia, which required continuous steroid treatment for 16 months.
Thereafter, she received 4 weekly doses of rituximab (375mg/m
2/dose) associated with steroid
therapy, which was then tapered over the subsequent 2 weeks. One month after the last dose of
rrituximab, she presented with recurrence of severe hemolysis and received two more doses of
rrituximab. The patient remained in clinical remission for 7 months, before presenting with a further
relapse. An alternative heavy immunosuppressive therapy was administered combining cyclopho-
sphamide 10mg/kg/day for 10 days with methylprednisolone 40mg/kg/day for 5 days, which was then
tapered down over 3 weeks. While still on steroid therapy, the patient developed an interstitial
pneumonia with Acute Respiratory Distress Syndrome, which required immediate admission to the
intensive care unit where extracorporeal membrane oxygenation therapy was administered
continuously for 37 days. At 16-month follow-up, the patient is alive and in good clinical condition,
with no organ dysfunction, free from any immunosuppressive treatment and with a normal Hb level.
Conclusions: This case shows that aggressive combined immunosuppressive therapy may lead to a
sustained complete remission in children with refractory autoimmune hemolytic anemia. However,
the severe life-threatening complication presented by our patient indicates that strict clinical
monitoring must be vigilantly performed, that antimicrobial prophylaxis should always be considered
and that experienced medical and nursing staff must be available, to deliver highly specialized
supportive salvage therapies, if necessary, during intensive care monitoring.
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Autoimmune hemolytic anemia (AIHA) in children is
usually characterized by a severe course with a mortality
rate of approximately 10% [1]. The required prolonged
immunosuppressive therapy often leads to steroid depen-
dence [2]. The administration of non-steroidal immuno-
suppressive drugs such as cyclosporine A,
cyclophosphamide and azathioprine, has been used in
the past [1–4]. Nowadays, the use of monoclonal
antibodies such as rituximab, has given promising results
for pediatric refractory AIHA [5–7], with sustained
remissions in the majority of patients. Nevertheless,
potentially life-threatening infections are known to occur
with rituximab [7]. In the event of rituximab failure, there
is no general consensus or guidelines available indicating
precisely how to manage resistant forms of AIHA. Heavy
immunosuppression consisting of the combined use of
cyclophosphamide and high-dose steroids may be con-
sidered [8, 9].
Case presentation
We report the case of an 8-month-old Caucasian girl
referred to us for observation due to intense pallor,
jaundice, lethargy and fever.S e r o l o g i c a levaluations
revealed severe anemia (Hb = 2.8g/dL) with a strongly
positive direct antiglobulin test and high-titer warm IgG
autoantibody. AIHA was diagnosed and steroid therapy
with intravenous methylprednisolone at 2mg/kg/day was
administered for 5 days (Figure 1). An adequate Hb
increase was obtained and the child was discharged after
10 days with oral prednisone at 2mg/kg/day.
During the subsequent months, several attempts were
made to taper off the prednisone, but the patient had
developed steroid dependence. Considering this depen-
dence on high steroid doses, a therapeutic course with four
doses of rituximab was performed (375mg/m
2/dose) at
weekly intervals (Figure 1). Before rituximab infusion,
serum immunoglobulin levels were normal and subpo-
pulation lymphocyte counts were within the normal
range. The treatment with rituximab was well tolerated
and the patient received intravenous substitutive therapy
with commercially available immunoglobulin
preparations (400mg/kg, every 3 weeks for 6 months).
One month after the end of the first course of rituximab,
while still receiving low-dose steroids, the patient pre-
sented with a clinical relapse of AIHA, so prednisone was
increased to 2mg/kg/day and two further rituximab
infusions were performed (Figure 1). After these infusions,
B lymphocytes became undetectable and the count
returned to normal values 8 months after treatment. The
patient remained in clinical remission and free from
immunosuppressive drugs for 7 months, before presenting
with a further relapse. A more intensive treatment was
performed (Figure 1) with cyclophosphamide 10mg/kg/
day for 10 days and methylprednisolone 40mg/kg/day for
5 days, which was tapered over 20 days. Hb level increased
and the patient was discharged 10 days later in good
clinical condition, without any antifungal or antiviral
prophylaxis.
Two weeks later, the child was referred to the Emergency
Room for respiratory failure, persistent fever and abdom-
inal pain. Laboratory examination showed an Hb level of
12.8g/dL, total leukocyte count (WBC) of 710/µL,
absolute neutrophil count (ANC) of 90/µL, a platelet
count (PLT) of 339,000/µL, and low levels of immuno-
globulin (IgG = 360mg/dL, IgA = 10mg/dL, IgM = 33mg/
dL). Chest X-ray and CT scan revealed an interstitial
pneumonia (Figure 2). Therapy with amikacin, ceftazi-
dime, G-CSF and voriconazole was started. Within a few
hours, her clinical condition deteriorated and the patient
developed Acute Respiratory Distress Syndrome (ARDS),
which required immediate admission to the intensive care
unit (ICU). Acceptable gas exchange was initially main-
tained by non-invasive continuous positive airway pres-
sure (Figure 3). Serologic tests showed a level of Aspergillus
galactomannan antigen of 0.8. All tested virus and
microbial antigens were negative. On day 4, concomi-
tantly with an elevation of WBC from 400 to 10,400/µL
(ANC = 4900/µL), respiratory conditions precipitated and
endotracheal intubation and mechanical ventilation were
started (Figure 3). A protective ventilatory strategy with
tidal volume of 6mL/kg and positive end expiratory
pressure (PEEP) of 10cmH2O was instituted.
In the following days, gas exchange deteriorated and PEEP
levels rose to 17cmH2O. Recruitment manoeuvres, prone
positioning, and high doses of inhaled nitric oxide (NOi)
were necessary to maintain viable gas exchange. Endo-
tracheal instillation of porcine surfactant and a trial with
High Frequency Oscillation were ineffective. On day 10,
owing to the refractory hypoxia, worsening hypercapnia,
and chest X-ray evidence of a pneumomediastinum, the
patient was placed on venous-venous extracorporeal
membrane oxygenation (ECMO) (Figure 3). A double
lumen 15 french catheter (Maquet, Jostra Medizintechnik
AG, Hirrlingen, Germany) was inserted into the right
Figure 1.
Immunosuppressive therapy administered during the course
of refractory autoimmune hemolytic anemia. mPDN, methyl-
prednisolone; Cy, cyclophosphamide; PDN, prednisone.
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polymethylpentene membrane oxygenator, permanent
life support and a centrifugal Rotaflow pump (Maquet,
Jostra Medizintechnik AG, Hirrlingen, Germany). ECMO
was started with a blood flow of 0.8 to 0.9 L/minute and
gas flow of 1 L/minute of 100% oxygen. Following the
institution of ECMO, respiratory rate decreased from 45 to
10 breaths/minute, and it was possible to stop NOi.
After commencing caspofungin with voriconazole, WBC,
ANC and C reactive protein (CRP) slowly decreased, while
pulmonary function slightly improved. On day 19, a
multidrug-resistant Pseudomonas aeruginosa was isolated
from bronchoaspirate (Figure 3). In spite of antibiotic
reinforcement with levofloxacin, Pseudomonas aerugi-
nosa antibiogram showed increased resistance to all
antibiotics and to colimicine which was started on day
26. On day 28, a sudden increase in resistance on the
return part of the circuit caused a massive thrombosis in
the oxygenator. The entire circuit and the cannula were
immediately changed and ECMO restarted within 2 hours.
Following the development of pulmonary embolism, the
gas exchange rapidly worsened and NOi had to be
restarted. An echocardiographic assessment showed right
ventricular dilatation, with paradoxical septal wall motion
and pulmonary hypertension (systolic pressure
90mmHg). Prostacyclin and sildenafil improved the
right heart function and effectively attenuated pulmonary
hypertension. In the following days, WBC, ANC and CRP
slowly decreased, while pulmonary function improved.
Thirty days from ICU admission, ECMO was stopped, the
patient rapidly restored her spontaneous ventilatory
functions and she was extubated 10 days later. She was
finally discharged from the ICU on day 44. At 16-month
follow-up, the patient is alive and free from immunosup-
pressive drugs. At the time of last follow-up, Hb level was
13.5g/dL, reticulocyte count was 11 × 10
9/L, with total
bilirubin, lactic dehydrogenase and haptoglobin all within
the normal ranges.
Discussion
AIHA in children younger than 2 years is in some cases
characterized by a resistance to corticosteroids or depen-
dence on high steroid doses and subsequent development
of severe side effects [2]. Splenectomy or immunomodu-
lating agents have frequently been used, but there is no
consistent demonstration of their efficacy in controlling
hemolysis [3]. Immunosuppressive drugs such as
azathioprine, cyclosporine A, or cyclophosphamide,
alone or in combination reduce steroid dependence and
sometimes control hemolysis [1–4]. Clinical experience
with monoclonal antibodies appears encouraging. In
particular, rituximab is increasingly being used off-label,
for difficult-to-treat auto-immune diseases and presents
the advantage of inducing a selective B-cell depletion,
sparing cellular immunity mediated by T cells and natural
killer cells. Even though prospective controlled studies are
not currently available, the efficacy of rituximab has been
shown in pediatric studies. Quartier et al. [5] treated five
pediatric refractory AIHA patients, who achieved a
complete remission within 15 to 22 months after
rituximab therapy. These results were confirmed by Zecca
et al. [6] in a group of 15 children treated with rituximab.
Four other children were treated by Motto et al. [7], with
the achievement of complete remission. Nevertheless, the
prolonged impairment of antibody production leads to an
increased risk of viral and bacterial infections. For this
reason, monthly intravenous immunoglobulin infusions
Figure 2.
Chest X-ray film sequence. (A) Day of admission to the
intensive care unit; (B) before extracorporeal membrane
oxygenation with evidence of pneumomediastinum (white
arrow), in spite of protective ventilatory strategy; (C) before
intensive care unit discharge showing a complete resolution of
acute respiratory distress syndrome.
Figure 3.
Main gas exchange (upper panel: PaO2/FiO2, and PaCO2),
ventilatory (middle panel: minute ventilation), and laboratory
(lower panel: white blood cell count WBC, absolute
neutrophil count ANC, and C reactive protein CRP) data
in intensive care unit. Vertical solid line refers to: (A)
endotracheal intubation; (B) connection to extracorporeal
membraneoxygenation;(C)disconnectionfromextracorporeal
membrane oxygenation. The black arrow indicates the first
positivity for Aspergillus galactomannan antigen in the patient’s
serum. The white arrow indicates the first microbiological
evidence of Pseudomonas aeruginosa.
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completion of therapy and prophylaxis for P. jirovecii
pneumonia is also suggested [7].
The patient described in our report received four rituximab
infusions in an off-label setting, followed by two
additional doses over 6 months. Clinical remission was
achieved for 7 months after which it was possible to
interrupt steroid treatment. The pattern of immune
reconstitution after rituximab therapy revealed persistently
low immunoglobulin levels, partially corrected by the
substitutive therapy. Immunoglobulin levels reached their
normal range in 18 months and the lymphocyte sub-
populations returned to normal range in 16 months. It is,
nevertheless, difficult to quantify the real role of rituximab
in this heavy immunosuppression, since a combined
therapy with high doses of methylprednisolone and
cyclophosphamide was subsequently started. Even though
our patient did not present any early side effects related to
the rituximab infusions, a prolonged follow-up should be
carried out to monitor and prevent long-term side effects
of rituximab, which are still unknown.
When our patient relapsed, an alternative treatment was
required, since therapies with steroids, rituximab and
intravenous immunoglobulins proved to be ineffective.
T h er o l eo fs p l e n e c t o m yi nr e f r a c t o r yA I H Ai ss t i l l
controversial [1–4]. Although effective vaccinations are
available, this surgical treatment should be avoided in
children younger than 6 years of age, due to the risk of
developing severe bacterial infections. According to local
policy, drug-based immunosuppressive therapy is to be
preferred. We therefore decided to adopt a combined
therapy approach, with high doses of methylprednisolone
(40mg/kg/day for 5 consecutive days), which was then
tapered down over 20 days, and cyclophosphamide
(10mg/kg/day for 10 consecutive days). This approach
appeared to be feasible and encouraging, since we had
previously successfully treated two pediatric cases of
refractory AIHA with an identical approach [8, 9]. The
administration of methylprednisolone and cyclophospha-
mide increased the already significant immunodepression
which had resulted from prior therapies and further
contributed to the severity of the infectious complication
presented by our patient that required ECMO therapy.
While in the ICU, the patient underwent various ventila-
tory treatments, some of which are not considered
conventional. Modern ventilatory strategy in ARDS aims
to provide viable gas exchange with high oxygen concen-
tration andPEEP, while minimizing theinjurious effects of
mechanical ventilation by using low tidal volume ventila-
tion (6mL/kg) [10]. Although other techniques such as the
prone position, NOi and recruitment manoeuvres are
effective in improving gas exchange, they did not prove
effective in terms of survival [10]. Nevertheless, before
ECMO, the only means of providing minimal acceptable
oxygenation was to use both NOi and the prone position.
Despite using low tidal volumes, a respiratory rate of up to
45 breaths/minute was necessary to obtain acceptable CO2
levels, and the occurrence of pneumomediastinum
demonstrated that we were unable to provide an effective
protective ventilatory strategy. Thus, ECMO was the only
real means of providing such a strategy, while allowing
adequate gas exchange.
Refractory AIHA in pediatric patients is a challenging
disease that forces us to weigh up the risks and benefits of
heavy and prolonged immunosuppressive therapies that
can reduce or even eradicate the hemolysis, despite the risk
of infectious complications. For this reason, we feel that
prolonged viral and fungal prophylaxis therapy should
always be considered, during and after the immunosup-
pressive therapy. Furthermore, strict clinical monitoring
should be carried out, even when no evident symptoms
are present. In our patient, we did not administer any
prophylaxis and clinical monitoring was probably delayed
for too long after discharge. Resolution of the infectious
complication was possible thanks to an advanced inten-
sive care assistance, which consisted of ECMO and the
management of its related complications.
Conclusions
This case study shows that rituximab-resistant AIHA in
young children represents a significant challenge, requir-
ing aggressive immunosuppressive therapy, which may
potentially cause severe life-threatening complications.
Nowadays, it is not clear which is the best immunosup-
pressive agent to be administered in the event of rituximab
failure. We found that the combination of methylpredni-
solone and cyclophosphamide could be a valid alter-
native, based on previous experience. Nevertheless, a
universal therapeutic flow-chart is still lacking and should
be defined, which considers new therapeutic strategies
such as alemtuzumab [11] or hematopoietic stem cell
transplantation [12]. What is clear, however, in the case of
heavy immunosuppressive therapy, is the importance of
strict patient monitoring during and after immunosup-
pressive therapy and an antimicrobial prophylaxis, parti-
cularly for fungal agents and P. jirovecii.
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